Hadasit Newsletter – April 2019
Hadassah Signs Master Research Agreement with Royal Philips
In October 2018 Hadasit signed a master agreement for collaborative clinical research with Royal Philips, the Amsterdam-based, global leader in healthcare technologies. Following a successful collaboration and the support of Hadassah Medical Center in the development of a revolutionary CT technology and the first-of-its-kind IQon Spectral CT, Hadassah and Philips have committed to continue their fruitful collaboration. Research will focus on assessment of acute neurological conditions, stroke imaging, and acute non-traumatic abdominal conditions using the IQon Spectral CT. The use of IQon Spectral CT in routine and emergency departments will also be studied.
The agreement opens the door for research initiatives from both sides with the funding opportunity from Philips, under agreed upon framework. Prof. Sosna, head of radiology, heads the steering committee of this collaboration from Hadassah’s side.
Do you have a relevant research project with Philips in mind? Contact Ariel Rabin at Hadasit: email@example.com
Hadassah Launches Medical Startup Accelerator with IBM
Hadasit has launched Hadassah Accelerator powered by IBM Alpha Zone – a new, 6-month incubation program for medical startups. The program focuses on seed/post-seed startup companies that are creating leading medical solutions for the global marketplace and can benefit from long-term technology and business partnerships with Hadassah and IBM. The first cohort of participants are currently being selected and are expected to start within the coming months.
Hadassah Accelerator is strategically located on the premises of the BioHouse workspace at Hadassah Ein Kerem Medical Center, providing companies direct access to hospital resources as well as medical and professional staff. IBM will provide expert technological advice and access to its advanced technological tools, including hosting on IBM Cloud. The Hadassah Accelerator is powered by IBM Alpha Zone Accelerator, which has already run seven classes with 52 graduates.
Innovation in Orthopedics & Dentistry: New License Agreement with Prudentix
Hadasit and Yissum signed a new research and license agreement with Prudentix, a company that develops innovative dental products. The agreement is based on a new technology developed by Dr. Amir Haze, Dr. Anat Blumenfeld and Prof. Dan Deutsch that uses recombinant Ameliogenin to repair cartilage, ligaments and tendons. Financial terms of the agreement include sponsoring ongoing research at Hadassah, royalties from sales, license fees and additional terms.
Pursuant to the agreement, a new orthopedic spin-off entity named “Planeeria” was established. Planeeria will further develop this promising technology for use in orthopedics as well as dentistry.
Planeeria was recently profiled in The Globes, Israel’s leading financial newspaper.
Hadassah GMP Facility Reaches 100% Capacity
New agreements signed with industrial companies have brought Hadassah’s GMP facility to full capacity. In 2018, the facility for biopharmaceutical production was upgraded and received approval from Israel’s Ministry of Health to produce products for Phase I, II & III clinical studies.
Tal Almog, VP Business Development, Pharma & Diagnostics
Tal Almog joined Hadasit in 2016. His work focusses on project evaluation, funding, and out-licensing of Hadasit’s portfolio of pharmaceuticals and molecular diagnostics projects. In addition, Tal actively promotes the R&D and consulting services of Hadassah researchers as a source of funding and a means of connecting with industry.
Before joining Hadasit, Tal served as Business Development Manager of Cellect Biotechnology, Ltd., and also managed R&D projects at the Lipid Center at Sheba Medical Center. He received both his PhD in biochemistry and molecular biology and his MBA from Tel Aviv University.
In 2018, under Tal’s leadership, Hadassah researchers and clinicians submitted a record-high seven Kamin grants; six of the seven grants were awarded funding. Three additional applications were submitted in March 2019 and Hadasit is preparing applications for the July and November deadlines. Hadasit hopes to break last year’s record for Kamin submissions and funding.
Kamin grants provide up to 660,000 NIS per year (up to two years) for industry-oriented research, primarily in the fields of pharma, diagnostics, and, to a lesser extent, medical devices. Kamin is an important tool for academic institutions in Israel because it allows them to receive funding for applicative research independent of companies or investors. Since Tal joined Hadasit, Kamin and Nofar funding in pharma and molecular diagnostics has yielded more than NIS 8 million for Hadassah researchers.
Please contact Tal at firstname.lastname@example.org for more details about Kamin/Nofar/Magneton grants.